Skip to main content
. 2022 Dec 8;6(2):e202201533. doi: 10.26508/lsa.202201533

Figure 6. Anti-CD45-SLAMF6 antibody enhances T cell response in primary human cell–based assay.

Figure 6.

PBMCs were treated with SEE and three different concentrations of either the monovalent (αCD45/SLAMF6) or the bivalent (αCD45-Ig-SLAMF6) anti-CD45/SLAMF6–bispecific antibody. (A, B) After 24 h, (A) IL-2 and (B) IFN-γ levels were measured by ELISA. The results of at least three independent experiments (n = 3) are shown. (C, D) Primary human CD3-positive T cells were isolated from whole blood and cultured with anti-CD3 in the presence αCD45/SLAMF6. (C) After 5 min, the cells were analyzed for phosphorylation of CD3 ζ chain using flow cytometry. (D) After 24 h, the cells were analyzed for CD69 expression, and the supernatant was analyzed for IL-2 and IFN-y release. *P < 0.05, **P < 0.01 for an unpaired t test.